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Background: Construction of artificial polyepitope antigens is one of the most promising strategies for developing
more efficient and safer vaccines evoking T-cell immune responses. Epitope rearrangements and utilization of
certain spacer sequences have been proven to greatly influence the immunogenicity of polyepitope constructs.
However, despite numerous efforts towards constructing and evaluating artificial polyepitope immunogens as well
as despite numerous computational methods elaborated to date for predicting T-cell epitopes, peptides binding to
TAP and for antigen processing prediction, only a few computational tools were currently developed for rational
design of polyepitope antigens.
Findings: Here we present a PolyCTLDesigner program that is intended for constructing polyepitope immunogens.
Given a set of either known or predicted T-cell epitopes the program selects N-terminal flanking sequences for
each epitope to optimize its binding to TAP (if necessary) and joins resulting oligopeptides into a polyepitope in a
way providing efficient liberation of potential epitopes by proteasomal and/or immunoproteasomal processing.
And it also tries to minimize the number of non-target junctional epitopes resulting from artificial juxtaposition of
target epitopes within the polyepitope. For constructing polyepitopes, PolyCTLDesigner utilizes known amino acid
patterns of TAP-binding and proteasomal/immunoproteasomal cleavage specificity together with genetic algorithm
and graph theory approaches. The program was implemented using Python programming language and it can be
used either interactively or through scripting, which allows users familiar with Python to create custom pipelines.
Conclusions: The developed software realizes a rational approach to designing poly-CTL-epitope antigens and can
be used to develop new candidate polyepitope vaccines. The current version of PolyCTLDesigner is integrated
with our TEpredict program for predicting T-cell epitopes, and thus it can be used not only for constructing the
polyepitope antigens based on preselected sets of T-cell epitopes, but also for predicting cytotoxic and helper
T-cell epitopes within selected protein antigens. PolyCTLDesigner is freely available from the project’s web site:
http://tepredict.sourceforge.net/PolyCTLDesigner.html.
Keywords: T-cell epitope, Polyepitope, Cytotoxic T cell, Transporters associated with antigen processing,
Proteasome, Directed weighted graph, Travelling salesman problemFindings
One of the most promising approaches to designing more
efficient and safer vaccines is construction of artificial
polyepitope antigens [1-6]. Their advantages over con-
ventional vaccines include reduced risk of developing
autoimmunity and other pathological conditions since
such constructions doesn’t contain whole microbial mo-
lecular structures and epitopes, sharing profound simi-
larity to human proteins. Besides, polyepitopes may* Correspondence: antonec@yandex.ru
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distribution, and reproduction in any mediumcontain both cytotoxic (CTL) and T-helper epitopes be-
longing to different antigens, including those of distinct
pathogenic microorganisms, thus making possible to
induce immune responses with a wider specificity. In
addition, polyepitopes may be designed taking into ac-
count the prevalences of certain HLA class I molecules
allomorphs within the target human population or even
within an individual patient. Polyepitopes may also be
constructed in a way maximizing efficiency of process-
ing and presentation of the majority of included epi-
topes [4,7-9]. Additional signal sequences (for example,
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be introduced into target polyepitopes to increase their
efficiency of stimulating either CD8+ and/or CD4+ T-cell
response [10-14]. However, despite numerous efforts
towards constructing artificial polyepitope immuno-
gens and evaluating their immunogenicity and protectivity
[2,4-9,15,16] and despite numerous computational methods
developed to date for predicting T-cell epitopes [17-20],
proteasomal cleavage sites [21-25], and peptide binding to
TAP (transporters associated with antigen processing)
[24,26-28], only a few computational tools intended for
rational design of polyepitope T-cell immunogens were
developed to date [29,30].
Both interaction of peptides with MHC molecules and
peptides binding to TAP complex are sufficiently spe-
cific for certain amino acid patterns. Proteasomal and
immunoproteasomal cleavage sites are also to a consid-
erable degree determined by the amino acid sequences
of antigens and degenerate amino acid motifs that de-
termine the efficiency of proteasomal cleavage sites are
currently known [22,31] as well as the motifs determining
the affinities of oligopeptides binding to TAP [26-28]. It
has been shown that a concurrent prediction of peptide
binding affinities for MHC molecules and TAP decreases
false positive rate when predicting T-cell epitopes [26,27].
As it has been experimentally demonstrated, that intro-
duction of spacer sequences to between individual epi-
topes could considerably increase the ability of such
polyepitope constructs to induce cytotoxic T-cell im-
mune responses [4,7,9]. Epitope rearrangements within
the polyepitopic constructs were also found to signifi-
cantly influence their immunogenicity and it was also
hypothesized that while constructing the polyepitope
antigen one should minimize the number of nontarget
junctional epitopes [9].
It has been shown that longer peptides transported
into the endoplasmic reticulum (ER) undergo N-terminal
trimming by ER aminopeptidases (ERAPs) to allow them
to bind MHC class I molecules [32], and that C-
termini of the epitopes are preferentially generated by
proteasomal cleavage [33-35]. Thus individual epitopes
within a polyepitope should be arranged in a way pro-
viding sufficiently efficient proteasomal cleavage sites
at their C-termini while, if necessary, their N-termini
might be flanked with certain amino acid residues to
optimize their binding to TAP.
The goal of this work was to develop a program
intended for rational design of polyepitope T-cell antigens
with a special focus on optimizing their immunogenicity
via selecting amino acid spacer sequences for each pair
of epitopes and choosing the optimal ordering of the
epitopes within the polyepitope.
A program named PolyCTLDesigner was developed.
Given a set of either known or predicted CTL epitopes,PolyCTLDesigner predicts affinity of their binding to
TAP and then N-termini of inefficient binders are ex-
tended with certain flanking residues using the model
created by Peters et al. [26], implying that the first three
N-terminal amino acid residues of the peptide and the
last C-terminal one are the major contributors to its
binding to TAP.
Then all possible pairs of obtained oligopeptides are
produced and PolyCTLDesigner predicts the proteasomal
and/or immunoproteasomal cleavage sites using the
models developed by Toes et al. [22]. According to the
chosen model, a spacer motif containing up to six amino
acid residues may be added when necessary after the C-
terminal residue of an epitope in order to optimize the
cleavage. For example, if the sequence ADLVKV is se-
lected as a spacer, PolyCTLDesigner tests the following
spacers: A, AD, ADL, ADLV, ADLVK, and ADLVKV and
it additionally considers the variant of a direct junction of
the epitopes. Besides, the program can also use degenerate
motifs, such as [ARSP][DLIT][LGA][VKA]. In this case,
all possible spacer sequences are generated and tested. An
optimal spacer is determined for each pair of epitopes; it
should (i) provide formation of the least number of non-
target epitopes at the epitopes junction; (ii) form efficient
proteasomal cleavage site at the C terminus of the first of
the epitopes in the pair; and (iii) it should be the shortest
of all, when the remaining parameters are equal. The opti-
mal spacer sequence is selected according to the following
ranking function:










Neps þ 0:05 NHLA þ 0:25
rankpr þ 0:25 rankimpr
where W is the weight (rank) of spacer sequence ss
between the epitopes pep1 and pep2; rankHLA is the rank
of non-target junctional epitope predicted to be the most
efficient binder for HLA class I allele HLA; freqHLA is the
genotypic frequency of that allele within the population of
interest (HLA alleles genotypic frequencies were taken
from dbMHC [36]); len(ss) is the length of spacer ss; rankpr
corresponds to the rank of proteasomal cleavage site pre-
dicted at the pep1 C-terminus (this value ranges from 1 to
11 with 1 and 11 corresponding to the most and the least
efficient proteasomal cleavage, respectively); rankimpr is
the rank of immunoproteasomal cleavage site; rankHLA
designates the mean rankHLA value; Neps is the number of
predicted junctional epitopes and NHLA is the number of
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sufficient affinity (currently PolyCTLDesigner predicts
T-cell epitopes with our program TEpredict [37], that
was recently updated); rankHLA value of 1 corresponds
to moderate binding affinity (6.3 ≤ pIC50 < 7.3), the value
of 2 corresponds to high affinity (7.3 ≤ pIC50 < 8.3) and
3 corresponds to the highest affinity (with predicted
pIC50 value ≥ 8.3). Thus the optimal spacer sequence
should have the least weight.
After optimal spacers are selected for each pair of
epitopes, PolyCTLDesigner constructs an incomplete
directed graph with nodes corresponding to peptides
(epitopes) and edges corresponding to allowed epitope
matchings. Each edge has two parameters: the optimal
spacer sequence and its weight which was calculated by
the ranking function described above. The constructed
weighted digraph is in turn transformed into a complete
one by adding edges corresponding to disallowed epitope
matchings; their weights are set to 5000 while the weights
of allowed epitope matchings usually don’t exceed 10.
The sequence of desired polyepitope antigen can be
determined as the least weighted complete simple path
in the constructed weighted digraph, and as one can
see this task is related to the travelling salesman prob-
lem (TSP). To find optimized sequence of polyepitope
antigen PolyCTLDesigner uses either greedy nearest
neighbor approach (only in the case of a nondegenerate
spacer sequence), or genetic algorithm-based TSP-solver
implemented in PyEvolve library [38]. The main steps of
PolyCTLDesigner algorithm are shown in Figure 1.Figure 1 PolyCTLDesigner workflow. (I) Prediction of affinity of peptides b
residues (when necessary); (II) selection of optimal spacer sequence for each
each peptide pair, should meet the following criteria: it should provide forma
should provide the least number of non-target junctional epitopes; and it sho
weighted graph with nodes corresponding to target epitopes and with edge
(III) construction of desired polyepitope immunogen amino acid sequence wBuilding the graph is the most time consuming step
and for a set of 40–50 peptides it can take about 6–8 hours
to be completed on typical desktop personal computer.
However in future we plan to implement parallelized algo-
rithm to reduce time consumption.
To illustrate the importance of poly-CTL-epitope
optimization we performed a small theoretical analysis:
six well-defined HLA-A*02:01-restricted HIV-1 CTL
epitopes were used to produce artificial polyepitopes
using our PolyCTLDesigner program. It was found that
probability of selecting an optimal epitopes permuta-
tion at random was less than 0.00139 and only 17% of
all possible polyepitope constructs did not contain in-
efficient proteasomal cleavage sites between target
CTL epitopes. Besides, the choice of spacer sequences
can have a great impact on proteasomal cleavage effi-
ciency, especially for certain peptides. The detailed
description of the study and its results can be found in
Additional file 1.
In addition, PolyCTLDesigner is also able to assist in
constructing polyepitope fragments containing T-helper
epitopes. Currently T-helper epitopes can be predicted
with ProPred models [39] (based on TEpitope models
[40]). From a set of proposed antigens the program selects
peptide fragments having 20–40 amino acid residues in
length which contain the maximal number of overlapping
T-helper epitopes restricted by maximal repertoire of
HLA class II allomorphs. Then, each fragment is extended
by five amino acid residues at both C- and N-terminals,
since residues flanking the core epitope can play aninding to TAP and addition of up to 3 N-terminal flanking amino acid
peptide pair (the optimal spacer, selected by the ranking function for
tion of proteasomal cleavage site at the C-terminus of the first peptide; it
uld have the shortest possible length) and construction of directed
s corresponding to allowed variants of their combinations; and
hich is determined as the longest simple path with a minimal weight.
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lymphocytes [41]. The fragments containing T-helper
epitopes can be joined through [KR][KR] motif, which
form cleavage sites for several lysosomal cathepsins in-
volved in antigen processing. It has been shown that
such motifs can increase the immunogenicity of individ-
ual T-cell epitopes [42,43].
The developed software realizes a rational approach to
designing highly immunogenic poly-CTL-epitope antigens
and can be used to develop new candidate polyepitope
vaccines. The current version of PolyCTLDesigner is inte-
grated with our TEpredict program for predicting T-cell
epitopes, and thus it can be used not only for constructing
the polyepitope antigens based on preselected sets of
T-cell epitopes, but also for predicting cytotoxic and
helper T-cell epitopes within selected protein antigens.
In addition, PolyCTLDesigner allows the user to select
a minimal set of epitopes covering a specified repertoire of
allelic variants of HLA molecules with a desired level of re-
dundancy. The program was implemented using Python
programming language and can be used either interactively
or through scripting, which allows the users familiar with
Python to create custom pipelines. PolyCTLDesigner
source code can be found in Additional file 2 and it is also
freely available at the project’s web site http://tepredict.
sourceforge.net/PolyCTLDesigner.html.
Methods
PolyCTLDesigner was implemented using the Python
programming language. The affinity of peptides binding
to TAP was predicted and the flanking sequences were
selected using the model developed by Peters et al. [26].
The models by Toes et al. [22] were used to predict
proteasomal and/or immunoproteasomal processing and
to select spacer sequences to optimize polyepitope pro-
cessing. The procedures involving graphs were realized
using Python graph library [44]. The poly-CTL-epitope
fragment was constructed with the help of genetic algo-
rithm using the PyEvolve library [38]. Biopython library
was used to read amino acid sequences written in Fasta or
GenBank format [45]. T-helper epitope predictions were
based on ProPred models [39]. CTL epitopes predictions
were made using our program TEpredict [37].
Availability and requirements
Project name: PolyCTLDesigner
Project home page: http://polyctldesigner.sourceforge.net
Operating system(s): platform-independent
Programming language: Python
Other requirements: Python 2.7, TEpredict (provided
with the PolyCTLDesigner), Biopython, NumPy, PyEvolve,
and Python graph
License: Creative Commons Attribution Non-Commercial
License V2.0 (CC BY-NC 2.0)Any restrictions to use by non-academics: see CC BY-NC
2.0 license
Additional files
Additional file 1: This file describes the short sample study of
designing artificial poly-CTL-epitope antigen composed of 6 well
studied HIV-1 CTL epitopes using PolyCTLDesigner.
Additional file 2: This file contains the source code of
PolyCTLDesigner together with a sample workflow script
(designer.py).
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